All stock lists
Lexicon Pharmaceuticals, Inc. (NASDAQ:LXRX)
US · Delayed Price · Currency is USD
Healthcare · Biotechnology
1.91+0.09 (+4.67%)
Market cap
$848M
Insider Score
Health Score
Analyst consensus
Listed since
Apr 7, 2000
Website
Insider Score
56/ 100
LXRX Insider Score
Bullish1 qualifying trade · 1 insider · $50.00K bought in the last 90 days
Financial Health Score
Fair
From LXRX’s reported statements · Q3 2026 (trailing 12 months)
Profitability0 / 20
Loses money on what it sells.
- Revenue
- $38.5M
- Net income
- -$61.3M
- Net margin
- -159.1%
Leverage20 / 20
Little or no net debt.
- Total debt
- $0
- Cash
- $44.1M
- Debt / equity
- 0.00
Liquidity20 / 20
Comfortably covers what is due within a year.
- Current assets
- $183.2M
- Current liabilities
- $17.8M
- Current ratio
- 10.31
Cash generation0 / 20
Consumes cash and must keep raising it.
- Operating cash flow
- -$49.2M
- Free cash flow
- -$49.2M
- FCF margin
- -127.8%
Dilution & runway5 / 20
Burning cash with under a year of runway — expect a raise.
- Shares outstanding
- 427.8M
- Share growth (1y)
- 17.7%
- Cash runway
- 11 months
Five pillars — profitability, leverage, liquidity, cash generation, dilution & runway — each scored 0–20 from the company’s own income statement, balance sheet and cash-flow statement, then scaled to 100. A pillar the statements cannot answer is left out rather than guessed; fewer than three and no score is shown.
LXRX Income Statement
| Fiscal Period | Q3 2026 | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 |
|---|---|---|---|---|---|---|
| Period Ending | Sep 30, 2026 | Jun 30, 2026 | Mar 31, 2026 | Dec 31, 2025 | Sep 30, 2025 | Jun 30, 2025 |
| Revenue | 11.25 M | 692.00 K | 21.10 M | 5.49 M | 14.18 M | 28.87 M |
| Revenue Growth (YoY) | -20.67 % | -97.60 % | 1572.11 % | -79.31 % | 710.40 % | 1652.64 % |
| Cost of Revenue | 79.00 K | 39.00 K | 108.00 K | 319.00 K | 10.00 K | 209.00 K |
| Gross Profit | 11.17 M | 653.00 K | 20.99 M | 5.17 M | 14.17 M | 28.66 M |
| SG&A Expense | 18.98 M | 9.75 M | 9.23 M | 8.76 M | 7.60 M | 9.35 M |
| R&D Expense | 30.20 M | 17.44 M | 12.76 M | 11.20 M | 18.76 M | 15.57 M |
| Operating Expenses | 25.67 M | 27.19 M | 21.99 M | 19.95 M | 26.36 M | 24.92 M |
| Operating Income | -14.49 M | -26.54 M | -996.00 K | -14.78 M | -12.19 M | 3.74 M |
| Pretax Income | -14.01 M | -31.77 M | -1.04 M | -15.53 M | -12.77 M | 3.25 M |
| Tax Provision | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Net Income | -12.96 M | -31.77 M | -1.04 M | -15.53 M | -12.77 M | 3.25 M |
| EPS (Basic) | -0.03 | -0.07 | -0.00 | -0.04 | -0.04 | 0.01 |
| EPS (Diluted) | -0.03 | -0.07 | -0.00 | -0.04 | -0.04 | 0.01 |
| Shares Outstanding | 427.78 M | 437.65 M | 400.24 M | 363.43 M | 363.40 M | 363.29 M |
Quarterly figures; YoY compares the same fiscal quarter a year earlier. Source: public market data.
Disclaimer — Informational only — not investment advice. Insider transaction data is sourced from SEC Form 4 filings; market data from public feeds and may be delayed. The Insider Score is a proprietary score for research purposes and does not predict future performance. Always do your own research.